This document is a published patent application from the USPTO, specifically application number US20260085076A1, filed on January 16, 2024, and published on March 26, 2026. It describes novel crystal forms (I and III) of an aromatic heterocyclic compound, a method for their production via solvent stirring, filtering, and drying, and their application in the production of drugs targeting diseases associated with abnormal JAK-STAT signaling pathways.

While this is a patent application and not a regulatory rule, it signifies potential future developments in pharmaceutical treatments. Companies involved in drug development, particularly those targeting JAK-STAT pathways, should be aware of this filing as it may impact intellectual property landscapes and future product pipelines. No immediate compliance actions are required for regulated entities, but monitoring patent filings is crucial for strategic planning in the pharmaceutical sector.